Identification of a Primary Target of Thalidomide Teratogenicity

Half a century ago, thalidomide was widely prescribed to pregnant women as a sedative but was found to be teratogenic, causing multiple birth defects. Today, thalidomide is still used in the treatment of leprosy and multiple myeloma, although how it causes limb malformation and other developmental d...

Full description

Saved in:
Bibliographic Details
Published inScience (American Association for the Advancement of Science) Vol. 327; no. 5971; pp. 1345 - 1350
Main Authors Ito, Takumi, Ando, Hideki, Suzuki, Takayuki, Ogura, Toshihiko, Hotta, Kentaro, Imamura, Yoshimasa, Yamaguchi, Yuki, Handa, Hiroshi
Format Journal Article
LanguageEnglish
Published Washington, DC American Association for the Advancement of Science 12.03.2010
The American Association for the Advancement of Science
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Half a century ago, thalidomide was widely prescribed to pregnant women as a sedative but was found to be teratogenic, causing multiple birth defects. Today, thalidomide is still used in the treatment of leprosy and multiple myeloma, although how it causes limb malformation and other developmental defects is unknown. Here, we identified cereblon (CRBN) as a thalidomide-binding protein. CRBN forms an E3 ubiquitin ligase complex with damaged DNA binding protein 1 (DDB1) and Cul4A that is important for limb outgrowth and expression of the fibroblast growth factor Fgf8 in zebrafish and chicks. Thalidomide initiates its teratogenic effects by binding to CRBN and inhibiting the associated ubiquitin ligase activity. This study reveals a basis for thalidomide teratogenicity and may contribute to the development of new thalidomide derivatives without teratogenic activity.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Article-2
ObjectType-Feature-1
ISSN:0036-8075
1095-9203
DOI:10.1126/science.1177319